Nov 15, 2022 / 12:25PM GMT
David Stanton - Jefferies Financial Group, Inc. - Analyst
And welcome to the Jefferies London Healthcare Conference. My name is Dave Stanton, I'm part of the Jefferies Australia healthcare research team. It's my absolute pleasure to have Megan Baldwin, CEO of Opthea with us today.
Opthea is improving vision in patients suffering from retinal eye diseases. It's developing a novel therapeutic called OPT-302, which is a VEGF-C/D 'trap' to be used in combination with existing standard of care anti-VEGF-A therapies. OPT-302 has the potential to address the unmet medical need of wet age-related macular degeneration and diabetic macular edema patients.
So, the format today is a presentation. So over to you, Megan, and thank you very much.
Megan Baldwin - Opthea Limited - CEO & MD
Good morning, everyone, and thank you very much, David, and thank you to the organizers for the opportunity to tell you a little bit more about Opthea all the way here in London.
So little bit about Opthea Limited. We are a dual-listed company. We trade ADRs on
Opthea Ltd at Jefferies London Healthcare Conference Transcript
Nov 15, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers